| Added by | pmartino |
|---|---|
| Group name | EquipePM |
| Item Type | Journal Article |
| Title | Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors |
| Creator | Sanchez-Martinez et al. |
| Author | Diego Sanchez-Martinez |
| Author | Nerea Allende-Vega |
| Author | Stefania Orecchioni |
| Author | Giovanna Talarico |
| Author | Amelie Cornillon |
| Author | Dang-Nghiem Vo |
| Author | Zhao-Yang Lu |
| Author | Ewelina Krzywinska |
| Author | Alberto Anel |
| Author | Eva M. Galvez |
| Author | Julian Pardo |
| Author | Bruno Robert |
| Author | Pierre Martineau |
| Author | Yosr Hicheri |
| Author | Francesco Bertolini |
| Author | Guillaume Cartron |
| Author | Martin Villalba |
| Abstract | Monoclonal antibodies (mAbs) have significantly improved the treatment of certain cancers. However, in general mAbs alone have limited therapeutic activity. One of their main mechanisms of action is to induce antibody-dependent cell-mediated cytotoxicity (ADCC), which is mediated by natural killer (NK) cells. Unfortunately, most cancer patients have severe immune dysfunctions affecting NK activity. This can be circumvented by the injection of allogeneic, expanded NK cells, which is safe. Nevertheless, despite their strong cytolytic potential against different tumors, clinical results have been poor. Methods: We combined allogeneic NK cells and mAbs to improve cancer treatment. We generated expanded NK cells (e-NK) with strong in vitro and in vivo ADCC responses against different tumors and using different therapeutic mAbs, namely rituximab, obinutuzumab, daratumumab, cetuximab and trastuzumab. Results: Remarkably, e-NK cells can be stored frozen and, after thawing, armed with mAbs. They mediate ADCC through degranulation-dependent and -independent mechanisms. Furthermore, they overcome certain anti-apoptotic mechanisms found in leukemic cells. Conclusion: We have established a new protocol for activation/expansion of NK cells with high ADCC activity. The use of mAbs in combination with e-NK cells could potentially improve cancer treatment. |
| Publication | Theranostics |
| Volume | 8 |
| Issue | 14 |
| Pages | 3856-3869 |
| Date | 2018 |
| Journal Abbr | Theranostics |
| Language | eng |
| DOI | 10.7150/thno.25149 |
| ISSN | 1838-7640 |
| Library Catalog | PubMed |
| Call Number | IMPACT: 8.537 |
| Extra | IMPACT: 8.537 PMID: 30083264 PMCID: PMC6071536 |
| Tags | Animals, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, antibody-dependent cell cytotoxicity (ADCC), Antineoplastic Agents, Immunological, cancer, Disease Models, Animal, fdf, Humans, Immunotherapy, inca, Killer Cells, Natural, Leukemia, Lymphocytic, Chronic, B-Cell, ligue, mabimprove, Mice, SCID, monoclonal antibodies (mAbs), NK cells, original, region, top, Transplantation, Homologous, Treatment Outcome |
| Date Added | 2018/08/21 - 08:38:45 |
| Date Modified | 2021/09/01 - 09:38:52 |
| Notes and Attachments | Full Text (Attachment) PubMed entry (Attachment) thnov08p3856s1.pdf (Attachment) |
Institut de Recherche en Cancérologie de
